Satish Kumar

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study

Pippa Corrie, Andrea Marshall, Janet Dunn et al. · The Lancet Oncology · 2014 · 109 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

Pippa Corrie, Pippa Corrie, Andrea Marshall et al. · Annals of Oncology · 2018 · 67 citations · Full text

Medicine, Clinical Sciences, Oncology +15

Deformity correction by external fixation and/or intramedullary nailing in hypophosphatemic rickets

Hae‐Ryong Song, Soma VVJ Raju, Satish Kumar et al. · Acta Orthopaedica · 2006 · 64 citations · Full text

Medicine, Orthopaedic Surgery, Orthopedic Surgery +7

Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)

Johnathan Joffe, Fay Cafferty, Laura Murphy et al. · Journal of Clinical Oncology · 2022 · 59 citations · Full text

Medicine, Oncology, Radiology +17